Compare Definium Therapeutics Inc. Common Shares (DFTX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs ProShares UltraPro S&P500 — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while ProShares UltraPro S&P500 trades at $154.94 (market cap $5.57B). The key difference: ProShares UltraPro S&P500 is the larger of the two by market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and ProShares UltraPro S&P500 for 29 Days on average.
| DFTX | UPRO | |
|---|---|---|
Market Cap | $4.71B | $5.57B |
Volume | 1,966,636 | 1,824,096 |
Sector | Health | Leveraged / Inverse |
52-Week High | $48.45 | $157.66 |
52-Week Low | $10.68 | $89.29 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $3.67B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UPRO trades at $155.21, down 0.77% on the day, while maintaining a bullish technical stance with strong moving average support. The stock shows neutral momentum oscillators but benefits from positive market sentiment around S&P 500 exposure. Recent news highlights strong corporate earnings growth expectations of 35% for 2026, though concerns exist about concentration risks in top holdings and potential profit growth slowdown to 15% in 2027.
The outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and AI-driven earnings growth, though investors face risks from market concentration, elevated valuations, and potential Federal Reserve policy impacts. Wall Street expects continued gains but acknowledges the need for selective positioning amid changing market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
